{
    "id": 3079,
    "fullName": "RET fusion",
    "impact": "fusion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "RET fusion indicates a fusion of the RET gene, but the fusion partner is unknown.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 5979,
        "geneSymbol": "RET",
        "terms": [
            "RET",
            "CDHF12",
            "CDHR16",
            "HSCR1",
            "MEN2A",
            "MEN2B",
            "MTC1",
            "PTC",
            "RET-ELE1"
        ]
    },
    "variant": "fusion",
    "createDate": "02/12/2015",
    "updateDate": "04/05/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6987,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetanib) treatment resulted in a disease control rate of 88% (15/17), median progression-free survival (PFS) of 4.7 months, and partial response in 53% (9/17) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9012)).",
            "molecularProfile": {
                "id": 2903,
                "profileName": "RET fusion"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6000,
                    "pubMedId": null,
                    "title": "A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study.",
                    "url": "http://meetinglibrary.asco.org/content/163941-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6990,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Caprelsa (vandetanib) treatment resulted in partial remission in 17% (3/18) and stable disease in 44% (8/18) of non-small cell lung adenocarcinoma patients harboring RET fusions (J Clin Oncol 34, 2016 (suppl; abstr 9013)).",
            "molecularProfile": {
                "id": 2903,
                "profileName": "RET fusion"
            },
            "therapy": {
                "id": 953,
                "therapyName": "Vandetanib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6002,
                    "pubMedId": null,
                    "title": "A phase II study of vandetanib in patients with non-small cell lung cancer harboring RET rearrangement.",
                    "url": "http://meetinglibrary.asco.org/content/166941-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 14143,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I/II trial (LIBRETTO-001), Selpercatinib (LOXO-292) treatment resulted in an objective response rate of 68% (71/105) in RET fusion-positive non-small cell lung cancer patients (IASLC 2019 World Conference on Lung Cancer, Sep 2019, abstract# PL02.08; NCT03157128).",
            "molecularProfile": {
                "id": 2903,
                "profileName": "RET fusion"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11479,
                    "pubMedId": null,
                    "title": "A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.",
                    "url": "https://meetinglibrary.asco.org/record/161573/abstract"
                },
                {
                    "id": 16259,
                    "pubMedId": null,
                    "title": "REGISTRATIONAL RESULTS OF LIBRETTO-001: A PHASE 1/2 TRIAL OF LOXO-292 IN PATIENTS WITH RET FUSION-POSITIVE LUNG CANCERS",
                    "url": "https://wclc2019.iaslc.org/wp-content/uploads/2019/08/WCLC2019-Abstract-Book_web-friendly.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14144,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Selpercatinib (LOXO-292) treatment resulted in an objective response rate of 83% (5/6) in RET fusion-positive papillary thyroid cancer patients (J Clin Oncol 36, 2018 (suppl; abstr 102); NCT03157128).",
            "molecularProfile": {
                "id": 2903,
                "profileName": "RET fusion"
            },
            "therapy": {
                "id": 5702,
                "therapyName": "Selpercatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3969,
                "name": "thyroid gland papillary carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11479,
                    "pubMedId": null,
                    "title": "A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.",
                    "url": "https://meetinglibrary.asco.org/record/161573/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2903,
            "profileName": "RET fusion",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}